☆ 4.6 Article

Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study

LANCET RESPIRATORY MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Infectious Diseases

The importance of influenza vaccination during the COVID-19 pandemic

John McCauley et al.

Summary: The COVID-19 pandemic has significantly impacted the circulation of influenza viruses, leading to a marked reduction in global influenza transmission. Despite this, influenza still poses a potential threat in many countries and vaccination remains the most effective preventive measure against influenza infections for the upcoming 2021-2022 season.

INFLUENZA AND OTHER RESPIRATORY VIRUSES (2022)

添加到收藏夹

Article Immunology

The disease burden of influenza beyond respiratory illness

Alejandro E. Macias et al.

Summary: Influenza, primarily known as a respiratory infection, also has broader consequences such as cardiovascular events, exacerbations of chronic illnesses, increased susceptibility to secondary infections, functional decline, and poor pregnancy outcomes. Understanding these broader consequences is crucial for assessing the full burden of influenza and the value of preventive measures among different populations.

VACCINE (2021)

添加到收藏夹

Review Immunology

Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis

Jason K. H. Lee et al.

Summary: Evidence over 10 consecutive influenza seasons and in more than 34 million individuals aged >= 65 years suggests that HD-IIV3 is consistently more effective than SD-IIV at reducing influenza cases as well as influenza-associated clinical complications irrespective of circulating strain and antigenic match.

VACCINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial

Rajeka Lazarus et al.

Summary: This study assessed the safety of concomitant administration of COVID-19 and influenza vaccines. The results showed that simultaneous vaccination with ChAdOx1 or BNT162b2 and an age-appropriate influenza vaccine raised no safety concerns and did not adversely affect immune responses.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Sara Y. Tartof et al.

Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.

LANCET (2021)

添加到收藏夹

Letter Medicine, General & Internal

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge

Lindsey R. Baden et al.

Summary: Participants who had previously received placebo in the trial were offered the mRNA-1273 vaccine in the open-label phase. The incidence of Covid-19 in this group was lower than those who had been vaccinated earlier, showing a modest decrease in vaccine efficacy over time.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Multidisciplinary Sciences

Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis

Adam Booth et al.

Summary: The study aims to analyze various clinical, demographic, and lifestyle variables associated with specific adverse outcomes in COVID-19 patients; by combining data from 17,860,001 patients across 14 countries, it identified many risk factors related to COVID-19, including age over 75, male sex, severe obesity, and active cancer.

PLOS ONE (2021)

添加到收藏夹

Editorial Material Immunology

Introductory paper: High-dose influenza vaccine Preface

Mia Diaco et al.

Summary: The high-dose influenza vaccine is significant for older adults, providing a more effective prevention measure against influenza and promoting healthy aging.

VACCINE (2021)

添加到收藏夹

Article Immunology

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

Laurence Chu et al.

Summary: The study evaluated the safety and immunogenicity of the mRNA-1273 vaccine in healthy adults, showing significant immune responses to SARS-CoV-2 with acceptable safety profile. This vaccine induced higher antibody levels at a 100 mg dose, confirming its immunogenicity and safety for use in a 2-dose regimen.

VACCINE (2021)

添加到收藏夹

Letter Virology

Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID-19 pandemic

Julian W. Tang et al.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas et al.

Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.

LANCET (2021)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2 dose-ranging study ,

Paul A. Goepfert et al.

Summary: The CoV2 preS dTM vaccine is being developed against SARS-CoV-2 and the interim results of the first-in-human study show lower than expected immune responses, especially in older age groups, and high reactogenicity after the second dose. Further development of the AS03-adjuvanted candidate vaccine will focus on identifying the optimal antigen formulation and dose.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Amy Flaxman et al.

Summary: The study shows that an extended interval before the second dose of the AstraZeneca vaccine leads to increased antibody titres, while a third dose significantly boosts antibody levels and enhances T-cell responses.

LANCET (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

Angela Choi et al.

Summary: The study demonstrates that both the mRNA-1273 COVID-19 vaccine and its variant-modified booster doses are safe and effective in improving neutralizing antibody titers against various virus variants.

NATURE MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

Ann R. Falsey et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Yinon M. Bar-On et al.

Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021

Mark W. Tenforde et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021

Eli S. Rosenberg et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

Wesley H. Self et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E. J. Anderson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Immunology

Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial

Lee-Jah Chang et al.

VACCINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Estimates of global seasonal influenza-associated respiratory mortality: a modelling study

A. Danielle Iuliano et al.

LANCET (2018)

添加到收藏夹

Review Immunology

Vaccination in the elderly: The challenge of immune changes with aging

Annalisa Ciabattini et al.

SEMINARS IN IMMUNOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults

Carlos A. DiazGranados et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Article Immunology

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults

David P. Greenberg et al.

VACCINE (2013)

添加到收藏夹

Article Immunology

Randomized, Double-Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High-Dose and Standard-Dose Influenza Vaccine in Adults 65 Years of Age and Older

Ann R. Falsey et al.

JOURNAL OF INFECTIOUS DISEASES (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.